Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
228 studies found for:    "Cytomegalic inclusion disease"
Show Display Options
Rank Status Study
1 Recruiting Donor Lymphocyte Infusion for Treatment of CMV Infection
Conditions: Stem Cell Transplantation, Hematopoietic;   CMV Infection;   Hematological Diseases
Interventions: Biological: DLI;   Biological: MSCs
2 Completed Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease
Condition: Cytomegalovirus Infections
Intervention: Drug: SDZ MSL-109
3 Completed Ganciclovir: Compassionate Use in Patients With Serious or Life-Threatening Cytomegalovirus Infections
Conditions: Cytomegalovirus Infections;   HIV Infections
Intervention: Drug: Ganciclovir
4 Completed Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient
Conditions: Cytomegalovirus Infections;   Cytomegalovirus Retinitis;   HIV Infections
Intervention: Drug: Ganciclovir
5 Completed A Pharmacokinetic and Tolerance Study of Oral Ganciclovir in HIV-Infected Children With Asymptomatic Cytomegalovirus Infection and Low CD4 Cell Counts or Quiescent Cytomegalovirus Disease
Conditions: Cytomegalovirus Infections;   HIV Infections
Intervention: Drug: Ganciclovir
6 Completed Clinical Evaluation of Ultrashort-term Heat Inactivation of Cytomegalovirus (CMV) Containing Raw Breast Milk to Prevent CMV-infection of Preterm Infants
Conditions: Cytomegalovirus Infection;   Preterm Infants
Intervention: Procedure: ultrashort heat inactivation
7 Recruiting A French Cohort of Transplant Recipients With CMV Infection : Risk Factors for Antiviral Resistance in the Prophylaxis Era.
Condition: Transplant Recipients With CMV Infection
Intervention: Biological: CMV Infection
8 Recruiting Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
Conditions: CMV Infection;   Persistent CMV Viremia
Intervention: Genetic: CMVpp65 Specific T-cells
9 Active, not recruiting The Influence of Chronic CMV Infection on Influenza Vaccine Responses
Conditions: Cytomegalovirus Infections;   Influenza
Intervention: Biological: Fluzone® 2012-2013 Formula
10 Unknown  Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients
Condition: Cytomegalovirus Disease
Interventions: Drug: Certican (everolimus) + valganciclovir;   Drug: Valganciclovir
11 Active, not recruiting Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection
Condition: Cytomegalovirus Disease
Interventions: Drug: Valganciclovir;   Biological: CMV hyperimmune globulin
12 Completed Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients
Condition: Cytomegalovirus Infection
13 Completed Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients
Condition: Cytomegalovirus Infection
Intervention: Drug: Single arm (ganciclovir and valganciclovir)
14 Completed Comparison of Two Test Methods-NASBA and Antigenemia-for Detecting Cytomegalovirus Infection
Conditions: Cytomegalovirus Infection;   Infection
15 Recruiting Evaluation of the PK and PD of Ganciclovir in Premature Infants Receiving Treatment for CMV Infection
Condition: Cytomegalovirus Infections
16 Active, not recruiting
Has Results
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
Condition: Cytomegalovirus Infection
Interventions: Drug: Placebo;   Drug: Valganciclovir
17 Completed gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females
Condition: Cytomegalovirus Infections
Interventions: Biological: MF-59;   Drug: Placebo;   Biological: CMV gB vaccine
18 Recruiting A Study of RG7667 for the Prevention of Cytomegalovirus Disease in Kidney Transplant Recipients
Condition: Cytomegalovirus Infections
Interventions: Drug: RG7667;   Drug: Placebo
19 Active, not recruiting Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
Condition: Cytomegalovirus Infections
Intervention: Drug: Maribavir
20 Terminated Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant
Condition: Cytomegalovirus Infections
Interventions: Drug: Valganciclovir;   Drug: Ganciclovir

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years